Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Damora Therapeutics, Inc.GLTO · Entity 4602 | Director | June 18, 2025 | June 20, 2025 |
| Design Therapeutics, Inc.DSGN · Entity 4991 | Director | June 09, 2026 | June 11, 2026 |
| INTERCEPT PHARMACEUTICALS, INC.ICPT · Entity 108343 | Chief Medical Officer | May 01, 2019 | May 03, 2019 |
| VivoSim Labs, INC.ONVO · Entity 8386 | Director | September 05, 2019 | September 09, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Damora Therapeutics, Inc.
Report date June 18, 2025 · Filed June 20, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.22 · Expires 2035-06-18 | Direct | 720 |
Reported balance
After 2025-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-18 · Grant · Acquired 720 · Balance 720 F1: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 18, 2025, the date of the Issuer's 2025 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 18, 2025, the date of the Issuer's 2025 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date.
Design Therapeutics, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.55 · Expires 2036-06-08 | Direct | 30,000 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the option vest in equal monthly installments over 12 months following June 9, 2026 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in equal monthly installments over 12 months following June 9, 2026 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders.
INTERCEPT PHARMACEUTICALS, INC.
Report date May 01, 2019 · Filed May 03, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 39,499 |
Ending reported balance
After 2019-05-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-05-01 · Exercise / conversion · Acquired 2,000 · Balance 41,499 F1: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person. Row 2 · 2019-05-01 · Sale · Disposed 2,000 · Balance 39,499 F1: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $31.90 · Expires 2023-05-07 | Direct | 9,031 |
Reported balance
After 2019-05-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-05-01 · Exercise / conversion · Disposed 2,000 · Balance 9,031 F1: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person. F2: This option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
F2: This option is fully vested and exercisable.
VivoSim Labs, INC.
Report date September 05, 2019 · Filed September 09, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.27 · Expires 2029-09-05 | Direct | 52,000 |
Reported balance
After 2019-09-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-09-05 · Grant · Acquired 52,000 · Balance 52,000 F1: The option represents an automatic annual award granted pursuant to the Issuer's non-employee director compensation plan. The option shares vest and become exercisable in full on the earlier of (i) September 5, 2020 or (ii) immediately prior to commencement of the Issuer's next annual stockholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The option represents an automatic annual award granted pursuant to the Issuer's non-employee director compensation plan. The option shares vest and become exercisable in full on the earlier of (i) September 5, 2020 or (ii) immediately prior to commencement of the Issuer's next annual stockholder meeting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2017 Filed Sep 5, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionOption to Purchase Common Stock · Derivative | 1,250 | $0.00 Strike: $31.90 | $0.00 |
DisclosureSEC source: 0001144204-17-046676 · v474655_form4.xml · derivative · entry 3 Shapiro David · CIK 0001559570 · CMO and EVP - Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,031 Underlying: Common Stock · 1,250 shares Expires 2023-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 1,250 | $117.43 | $146,787.50 |
DisclosureSEC source: 0001144204-17-046676 · v474655_form4.xml · nonDerivative · entry 2 Shapiro David · CIK 0001559570 · CMO and EVP - Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,562 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionCommon Stock | 1,250 | $31.90 | $39,875.00 |
DisclosureSEC source: 0001144204-17-046676 · v474655_form4.xml · nonDerivative · entry 1 Shapiro David · CIK 0001559570 · CMO and EVP - Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person. Read SEC document |
| August 01, 2017 Filed Aug 2, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionOption to Purchase Common Stock · Derivative | 1,118 | $0.00 Strike: $8.67 | $0.00 |
DisclosureSEC source: 0001144204-17-040073 · v472268_form4.xml · derivative · entry 3 Shapiro David · CIK 0001559570 · CMO and EVP - Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,118 shares Expires 2021-10-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| August 01, 2017 Filed Aug 2, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 1,118 | $119.00 | $133,042.00 |
DisclosureSEC source: 0001144204-17-040073 · v472268_form4.xml · nonDerivative · entry 2 Shapiro David · CIK 0001559570 · CMO and EVP - Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,562 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person. Read SEC document |
| August 01, 2017 Filed Aug 2, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionCommon Stock | 1,118 | $8.67 | $9,689.37 |
DisclosureSEC source: 0001144204-17-040073 · v472268_form4.xml · nonDerivative · entry 1 Shapiro David · CIK 0001559570 · CMO and EVP - Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person. Read SEC document |
| July 11, 2017 Filed Jul 13, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 553 | $124.01 | $68,577.53 |
DisclosureSEC source: 0001144204-17-036753 · v470756_4.xml · nonDerivative · entry 1 Shapiro David · CIK 0001559570 · CMO and EVP - Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,562 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person. Read SEC document |
| July 03, 2017 Filed Jul 5, 2017 21:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 100 | $121.35 | $12,135.00 |
DisclosureSEC source: 0001144204-17-035812 · v470323_form4.xml · nonDerivative · entry 2 Shapiro David · CIK 0001559570 · CMO and EVP - Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,115 F1 · kind: Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee. Read SEC document |
| July 03, 2017 Filed Jul 5, 2017 21:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 250 | $121.20 | $30,300.00 |
DisclosureSEC source: 0001144204-17-035812 · v470323_form4.xml · nonDerivative · entry 1 Shapiro David · CIK 0001559570 · CMO and EVP - Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,215 F1 · kind: Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee. Read SEC document |
| May 01, 2017 Filed May 3, 2017 21:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionOption to Purchase Common Stock · Derivative | 1,117 | $0.00 Strike: $8.67 | $0.00 |
DisclosureSEC source: 0001144204-17-024326 · v466056_4.xml · derivative · entry 3 Shapiro David · CIK 0001559570 · CMO and EVP - Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,118 Underlying: Common Stock · 1,117 shares Expires 2021-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| May 01, 2017 Filed May 3, 2017 21:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 1,117 | $112.18 | $125,305.06 |
DisclosureSEC source: 0001144204-17-024326 · v466056_4.xml · nonDerivative · entry 2 Shapiro David · CIK 0001559570 · CMO and EVP - Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,465 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person. Read SEC document |
| May 01, 2017 Filed May 3, 2017 21:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionCommon Stock | 1,117 | $8.67 | $9,680.70 |
DisclosureSEC source: 0001144204-17-024326 · v466056_4.xml · nonDerivative · entry 1 Shapiro David · CIK 0001559570 · CMO and EVP - Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,582 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person. Read SEC document |
| April 10, 2017 Filed Apr 11, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 558 | $108.51 | $60,548.58 |
DisclosureSEC source: 0001144204-17-020065 · v464077_4.xml · nonDerivative · entry 1 Shapiro David · CIK 0001559570 · CMO and EVP - Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,465 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 346 | $115.00 | $39,789.07 |
DisclosureSEC source: 0001144204-17-019295 · v463647_4.xml · nonDerivative · entry 1 Shapiro David · CIK 0001559570 · CMO and EVP - Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,023 F1 · kind: Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 21:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionOption to Purchase Common Stock · Derivative | 1,350 | $0.00 Strike: $21.50 | $0.00 |
DisclosureSEC source: 0001144204-17-012809 · v461097_4.xml · derivative · entry 3 Shapiro David · CIK 0001559570 · CMO and EVP - Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,786 Underlying: Common Stock · 1,350 shares Expires 2022-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 21:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 1,350 | $128.66 | $173,691.00 |
DisclosureSEC source: 0001144204-17-012809 · v461097_4.xml · nonDerivative · entry 2 Shapiro David · CIK 0001559570 · CMO and EVP - Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,369 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 21:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionCommon Stock | 1,350 | $21.50 | $29,025.00 |
DisclosureSEC source: 0001144204-17-012809 · v461097_4.xml · nonDerivative · entry 1 Shapiro David · CIK 0001559570 · CMO and EVP - Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $107.18 | $0.00 |
DisclosureSEC source: 0001144204-17-006032 · v458366_4.xml · derivative · entry 2 Shapiro David · CIK 0001559570 · CMO and EVP - Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-02-01 F2 · derivative.exercise_date: 25% of the shares of common stock underlying this option will vest on January 1, 2018, subject to the terms and conditions of the award and the 2012 Plan. The remainder of the shares of common stock underlying this option will vest pro rata on a monthly basis after the initial vesting date through January 1, 2021 (representing the vesting on each such vesting date of approximately 2.0833% of the shares of common stock initially underlying this option), subject to the terms and conditions of the award and the 2012 Plan. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-006032 · v458366_4.xml · nonDerivative · entry 1 Shapiro David · CIK 0001559570 · CMO and EVP - Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,369 F1 · shares: 25% of the shares of restricted stock will vest on January 1, 2018, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"). The remaining shares of restricted stock will vest pro rata on every subsequent three-month anniversary of the initial vesting date through January 1, 2021 (representing the vesting on each such vesting date of 6.25% of the shares of restricted stock), subject to the terms and conditions of the award and the 2012 Plan. Read SEC document |
| January 09, 2017 Filed Jan 11, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 1,565 | $106.01 | $165,905.65 |
DisclosureSEC source: 0001144204-17-001887 · v456743_4.xml · nonDerivative · entry 1 Shapiro David · CIK 0001559570 · CMO and EVP - Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,369 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 21:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 988 | $103.92 | $102,672.07 |
DisclosureSEC source: 0001144204-17-000940 · v456335_4.xml · nonDerivative · entry 1 Shapiro David · CIK 0001559570 · CMO and EVP - Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,934 F1 · kind: Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee. Read SEC document |
| December 02, 2016 Filed Dec 6, 2016 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 1,350 | $99.75 | $134,662.50 |
DisclosureSEC source: 0001144204-16-138201 · v454514_4.xml · nonDerivative · entry 1 Shapiro David · CIK 0001559570 · CMO and EVP - Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,922 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person. Read SEC document |
| October 10, 2016 Filed Oct 12, 2016 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 411 | $153.34 | $63,022.74 |
DisclosureSEC source: 0001144204-16-127903 · v450475_4.xml · nonDerivative · entry 1 Shapiro David · CIK 0001559570 · CMO and EVP - Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,272 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 21:06 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionOption to Purchase Common Stock · Derivative | 1,350 | $0.00 Strike: $21.50 | $0.00 |
DisclosureSEC source: 0001144204-16-127098 · v450070_4.xml · derivative · entry 4 Shapiro David · CIK 0001559570 · CMO and EVP - Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,486 Underlying: Common Stock · 1,350 shares Expires 2022-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person. F2 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 21:06 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 163 | $163.20 | $26,601.55 |
DisclosureSEC source: 0001144204-16-127098 · v450070_4.xml · nonDerivative · entry 3 Shapiro David · CIK 0001559570 · CMO and EVP - Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,683 F3 · kind: Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 21:06 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 1,350 | $163.06 | $220,131.00 |
DisclosureSEC source: 0001144204-16-127098 · v450070_4.xml · nonDerivative · entry 2 Shapiro David · CIK 0001559570 · CMO and EVP - Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,846 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 21:06 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionCommon Stock | 1,350 | $21.50 | $29,025.00 |
DisclosureSEC source: 0001144204-16-127098 · v450070_4.xml · nonDerivative · entry 1 Shapiro David · CIK 0001559570 · CMO and EVP - Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person. Read SEC document |
| September 26, 2016 Filed Sep 28, 2016 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 886 | $166.03 | $147,102.58 |
DisclosureSEC source: 0001144204-16-125866 · v449570_4.xml · nonDerivative · entry 2 Shapiro David · CIK 0001559570 · CMO and EVP - Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,846 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person. Read SEC document |
| September 26, 2016 Filed Sep 28, 2016 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 2,659 | $164.76 | $438,097.11 |
DisclosureSEC source: 0001144204-16-125866 · v449570_4.xml · nonDerivative · entry 1 Shapiro David · CIK 0001559570 · CMO and EVP - Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,732 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $164.5201 to $165.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.